Pharmaceutical News

WASHINGTON--(BUSINESS WIRE)--A new state-by-state analysis released today by HEAL Collaborative provides further insight into how hospitals participating in the 340B program are allocating resources. The study, titled "The 340B Drug Pricing Program by State: How Covered Entities Are Failing to Invest in Patient Care," was conducted by Magnolia Market Access and provides the first detailed look at how hospitals participating in the federal 340B drug discount program are utilizing program revenue...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a g...

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Boa...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025. “Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2’s boron chemistry pipeline and...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen’s scientific...

AUSTIN, Texas--(BUSINESS WIRE)--Surf Therapeutics, a clinical-stage company developing non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases, today reported positive first-in-human study results and announced the close of an extension seed financing round, bringing the company’s total funding to approximately $6 million. The funding follows the successful completion of a multi-center, single-blind, sham-controlled, cross-over study in 14 participants, including adu...

IRVINE, Calif.--(BUSINESS WIRE)--RIS Rx unveils new brand highlighting real-time GTN Revenue Protection, helping pharma manufacturers stop revenue leakage and protect patients....

WINNETKA, Ill.--(BUSINESS WIRE)--Hadley's free video series on the emotional impact of vision loss draws its strongest early response, pointing to a gap in vision care....

SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL-15 and IL-18 programs will be presented at the 2026 AACR Annual Meeting held April 17-22, 2026 in San Diego, California. IL-15 Programs: FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein and has demonstrated best-in-class (BIC) profile as monothera...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan announced today that it will have multiple presentations at ACC.26, taking place on March 28-30, 2026, in New Orleans....